Cost-effectiveness analysis results from the base case
| Strategy . | Discounted cost, $ . | Incremental cost, $ . | Discounted QALYs . | Incremental QALYs . | ICER, $/QALY . |
|---|---|---|---|---|---|
| Comparator with ibrutinib as second-line therapy | 336 418 | 3.09 | |||
| Ibrutinib as initial therapy | 791 670 | 455 252 | 5.49 | 2.40 | 189 326 |
| Strategy . | Discounted cost, $ . | Incremental cost, $ . | Discounted QALYs . | Incremental QALYs . | ICER, $/QALY . |
|---|---|---|---|---|---|
| Comparator with ibrutinib as second-line therapy | 336 418 | 3.09 | |||
| Ibrutinib as initial therapy | 791 670 | 455 252 | 5.49 | 2.40 | 189 326 |
Ibrutinib as first-line therapy was modeled to cost an additional $455 000 in health care costs and add an additional 2.40 QALYs compared with the modeled comparator, which assumes ibrutinib as second-line therapy. Costs are from a Medicare perspective and include additional health care costs.